bf109k4跟bf109g10

Searching…

www.accessdata.fda.gov

label - accessdata.fda.gov

Do not administer ONIVYDE to patients with bowel obstruction. Withhold ONIVYDE for diarrhea of Grade 2-4 severity. Administer loperamide for late diarrhea of any severity. Administer...

www.onivyde.com

NAPOLI 3 Recommended Dosing - ONIVYDE

The recommended dosing and administration of ONIVYDE® (irinotecan liposome injection) + oxaliplatin + FU/LV are detailed. Please see Important Safety Information and full Prescribing Information, including BOXED WARNING.

www.ema.europa.eu

Onivyde pegylated liposomal, INN-Irinotecan hydrochloride...

ONIVYDE pegylated liposomal must only be prescribed and administered to patients by healthcare professionals experienced in the use of anti-cancer therapies. ONIVYDE pegylated liposomal is not equivalent to non-liposo...

www.accessdata.fda.gov

label - Food and Drug Administration

ONIVYDE® is indicated, in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following...

www.ipsen.com

DOSAGE FORMS AND STRENGTHS - Global

YDE® (irinotecan liposome injection), for intravenous use Initial U.S. Approval: 1996 WARNING: SEVERE NEUTROPENIA and SEVERE DIARRHEA See full prescribing information for complete boxed warning Fatal neutro. enic seps...

www.onivyde.com

ONIVYDE® (irinotecan liposome injection) | Health Care...

Administer loperamide for late diarrhea of any severity. Administer atropine, if not contraindicated, for early diarrhea of any severity. CONTRAINDICATIONS. ONIVYDE is contraindicated in patients who have experienced ...